For personal use only

ASX / MEDIA RELEASE
Melbourne, Australia
Wednesday, 24 February, 2010

Compumedics Limited

Banking refinance completed

Leading Australia-based medical diagnostic devices company, Compumedics Limited (ASX: CMP), is pleased announce that it has secured new and strengthened banking arrangements with one of Australia's leading banking groups.

The new facilities, which are currently being put in place, are on terms and conditions that will meet the anticipated working capital needs of the Company.

The new facilities which total approximately $4m, comprise term loan, working capital and other credit facilities, of which about 40% are currently being utilised.

The Company plans to release its interim results to market tomorrow, Thursday, 25 February, 2010.

For Further information:
Mr David Burton
Executive Chairman, CEO
Phone: + 61 3 8420 7300
Fax: +61 3 8420 7399

Mr David Lawson
Chief Financial Officer
Phone: + 61 3 8420 7300
Fax: +61 3 8420 7399

Investor Relations & Media Enquires:
Mr Rod North
Executive Director
Bourse Communications Pty Ltd
Phone: +61 3 9510 8309

Mobile: +61 (0) 408 670 706

About Compumedics
Compumedics Limited, founded in 1987, is a global leader in the design and manufacture of diagnostic technologies for sleep disorders, neurophysiology and cardiology. In 1987 Compumedics established Asia Pacific's first fully computerised sleep laboratory. Compumedics holds 80% share of the Australian sleep-diagnostic market, and has a major and rapidly growing presence in the US, European and Asian marketplaces for its sleep, neurological and Doppler blood-flow diagnostic monitoring devices. **In 1995** the company was selected to supply equipment to the US Sleep Heart Health Study, the world's largest sleep study of its kind, currently exceeding 14,000 studies with 20,000 patients scheduled by 2008. With headquarters in Melbourne, Australia and offices in the United States, and Europe the products are distributed in over 50 countries. **In 1998** Compumedics was awarded the overall Australian Exporter of the Year. In **2000** Compumedics was listed on the Australian Stock Exchange. **In 2002**, Compumedics acquired US-based Neuroscan - the world's leading supplier of instruments for brain-research. In the US - the world's largest medical device market - Neuroscan holds around 90% of the market for brain-research products. **In 2003** Compumedics was awarded the Frost & Sullivan Award for Market Expansion Strategy. **In 2004**, Compumedics acquired German-based DWL Elektronishe GmbH, enabling Compumedics to expand its global operations into the neurovascular and cardio-vascular diagnostic fields. **In 2006**, Compumedics was awarded the Frost and Sullivan Technology Leadership award for the innovative Somté recorder product. **In 2007**, Compumedics and Chairman were inducted into the Victorian Manufacturing Hall of Fame. **In 2008** the DWL division received the top 100 German Innovation award. With 20,000 systems installed globally across the finest hospital, universities and clinics the Compumedics sales have grown more than 4 fold from $9 million (1999) to $38 million (2009). **In 2009** Compumedics was awarded a design award for its Grael® PSG/EEG premium laboratory based product.
www.compumedics.com

For personal use only